PURPOSE: A significant number of women with serous ovarian cancer are intrinsically refractory to platinum-based treatment. We analyzed somatic DNA copy number variation and gene expression data to identify key mechanisms associated with primary resistance in advanced-stage serous cancers. EXPERIMENTAL DESIGN: Genome-wide copy number variation was measured in 118 ovarian tumors using high-resolution oligonucleotide microarrays. A well-defined subset of 85 advanced-stage serous tumors was then used to relate copy number variation to primary resistance to treatment. The discovery-based approach was complemented by quantitative-PCR copy number analysis of 12 candidate genes as independent validation of previously reported associations with clinical outcome. Likely copy number variation targets and tumor molecular subtypes were further characterized by gene expression profiling. RESULTS: Amplification of 19q12, containing cyclin E (CCNE1), and 20q11.22-q13.12, mapping immediately adjacent to the steroid receptor coactivator NCOA3, was significantly associated with poor response to primary treatment. Other genes previously associated with copy number variation and clinical outcome in ovarian cancer were not associated with primary treatment resistance. Chemoresistant tumors with high CCNE1 copy number and protein expression were associated with increased cellular proliferation but so too was a subset of treatment-responsive patients, suggesting a cell-cycle independent role for CCNE1 in modulating chemoresponse. Patients with a poor clinical outcome without CCNE1 amplification overexpressed genes involved in extracellular matrix deposition. CONCLUSIONS: We have identified two distinct mechanisms of primary treatment failure in serous ovarian cancer, involving CCNE1 amplification and enhanced extracellular matrix deposition. CCNE1 copy number is validated as a dominant marker of patient outcome in ovarian cancer.
PURPOSE: A significant number of women with serous ovarian cancer are intrinsically refractory to platinum-based treatment. We analyzed somatic DNA copy number variation and gene expression data to identify key mechanisms associated with primary resistance in advanced-stage serous cancers. EXPERIMENTAL DESIGN: Genome-wide copy number variation was measured in 118 ovarian tumors using high-resolution oligonucleotide microarrays. A well-defined subset of 85 advanced-stage serous tumors was then used to relate copy number variation to primary resistance to treatment. The discovery-based approach was complemented by quantitative-PCR copy number analysis of 12 candidate genes as independent validation of previously reported associations with clinical outcome. Likely copy number variation targets and tumor molecular subtypes were further characterized by gene expression profiling. RESULTS: Amplification of 19q12, containing cyclin E (CCNE1), and 20q11.22-q13.12, mapping immediately adjacent to the steroid receptor coactivator NCOA3, was significantly associated with poor response to primary treatment. Other genes previously associated with copy number variation and clinical outcome in ovarian cancer were not associated with primary treatment resistance. Chemoresistant tumors with high CCNE1 copy number and protein expression were associated with increased cellular proliferation but so too was a subset of treatment-responsive patients, suggesting a cell-cycle independent role for CCNE1 in modulating chemoresponse. Patients with a poor clinical outcome without CCNE1 amplification overexpressed genes involved in extracellular matrix deposition. CONCLUSIONS: We have identified two distinct mechanisms of primary treatment failure in serous ovarian cancer, involving CCNE1 amplification and enhanced extracellular matrix deposition. CCNE1 copy number is validated as a dominant marker of patient outcome in ovarian cancer.
Authors: I Vergote; G J Rustin; E A Eisenhauer; G B Kristensen; E Pujade-Lauraine; M K Parmar; M Friedlander; A Jakobsen; J B Vermorken Journal: J Natl Cancer Inst Date: 2000-09-20 Impact factor: 13.506
Authors: A J Paige; K J Taylor; C Taylor; S G Hillier; S Farrington; D Scott; D J Porteous; J F Smyth; H Gabra; J E Watson Journal: Proc Natl Acad Sci U S A Date: 2001-09-25 Impact factor: 11.205
Authors: S Suzuki; D H Moore; D G Ginzinger; T E Godfrey; J Barclay; B Powell; D Pinkel; C Zaloudek; K Lu; G Mills; A Berchuck; J W Gray Journal: Cancer Res Date: 2000-10-01 Impact factor: 12.701
Authors: John Farley; Leia M Smith; Kathleen M Darcy; Eugene Sobel; Dennis O'Connor; Benita Henderson; Larry E Morrison; Michael J Birrer Journal: Cancer Res Date: 2003-03-15 Impact factor: 12.701
Authors: Cheryl A Sherman-Baust; Ashani T Weeraratna; Leticia B A Rangel; Ellen S Pizer; Kathleen R Cho; Donald R Schwartz; Teresa Shock; Patrice J Morin Journal: Cancer Cell Date: 2003-04 Impact factor: 31.743
Authors: S Makhija; A Sit; R Edwards; K Aufman; H Weiss; A Kanbour-Shakir; W Gooding; G D'Angelo; R Ferrell; S Raja; T E Godfrey Journal: Gynecol Oncol Date: 2003-07 Impact factor: 5.482
Authors: Francisco J Candido-dos-Reis; Honglin Song; Ellen L Goode; Julie M Cunningham; Brooke L Fridley; Melissa C Larson; Kathryn Alsop; Ed Dicks; Patricia Harrington; Susan J Ramus; Anna de Fazio; Gillian Mitchell; Sian Fereday; Kelly L Bolton; Charlie Gourley; Caroline Michie; Beth Karlan; Jenny Lester; Christine Walsh; Ilana Cass; Håkan Olsson; Martin Gore; Javier J Benitez; Maria J Garcia; Irene Andrulis; Anna Marie Mulligan; Gord Glendon; Ignacio Blanco; Conxi Lazaro; Alice S Whittemore; Valerie McGuire; Weiva Sieh; Marco Montagna; Elisa Alducci; Siegal Sadetzki; Angela Chetrit; Ava Kwong; Susanne K Kjaer; Allan Jensen; Estrid Høgdall; Susan Neuhausen; Robert Nussbaum; Mary Daly; Mark H Greene; Phuong L Mai; Jennifer T Loud; Kirsten Moysich; Amanda E Toland; Diether Lambrechts; Steve Ellis; Debra Frost; James D Brenton; Marc Tischkowitz; Douglas F Easton; Antonis Antoniou; Georgia Chenevix-Trench; Simon A Gayther; David Bowtell; Paul D P Pharoah Journal: Clin Cancer Res Date: 2014-11-14 Impact factor: 12.531
Authors: George Au-Yeung; Franziska Lang; Walid J Azar; Chris Mitchell; Kate E Jarman; Kurt Lackovic; Diar Aziz; Carleen Cullinane; Richard B Pearson; Linda Mileshkin; Danny Rischin; Alison M Karst; Ronny Drapkin; Dariush Etemadmoghadam; David D L Bowtell Journal: Clin Cancer Res Date: 2016-09-23 Impact factor: 12.531
Authors: Dariush Etemadmoghadam; Barbara A Weir; George Au-Yeung; Kathryn Alsop; Gillian Mitchell; Joshy George; Sally Davis; Alan D D'Andrea; Kaylene Simpson; William C Hahn; David D L Bowtell Journal: Proc Natl Acad Sci U S A Date: 2013-11-11 Impact factor: 11.205
Authors: Roel G W Verhaak; Pablo Tamayo; Ji-Yeon Yang; Diana Hubbard; Hailei Zhang; Chad J Creighton; Sian Fereday; Michael Lawrence; Scott L Carter; Craig H Mermel; Aleksandar D Kostic; Dariush Etemadmoghadam; Gordon Saksena; Kristian Cibulskis; Sekhar Duraisamy; Keren Levanon; Carrie Sougnez; Aviad Tsherniak; Sebastian Gomez; Robert Onofrio; Stacey Gabriel; Lynda Chin; Nianxiang Zhang; Paul T Spellman; Yiqun Zhang; Rehan Akbani; Katherine A Hoadley; Ari Kahn; Martin Köbel; David Huntsman; Robert A Soslow; Anna Defazio; Michael J Birrer; Joe W Gray; John N Weinstein; David D Bowtell; Ronny Drapkin; Jill P Mesirov; Gad Getz; Douglas A Levine; Matthew Meyerson Journal: J Clin Invest Date: 2012-12-21 Impact factor: 14.808
Authors: Fernanda Musa; Amandine Alard; Gizelka David-West; John P Curtin; Stephanie V Blank; Robert J Schneider Journal: Mol Cancer Ther Date: 2016-05-16 Impact factor: 6.261
Authors: Chang Xu; Yan Liu; Pei Wang; Wenhong Fan; Tessa C Rue; Melissa P Upton; John R Houck; Pawadee Lohavanichbutr; David R Doody; Neal D Futran; Lue Ping Zhao; Stephen M Schwartz; Chu Chen; Eduardo Méndez Journal: Mol Cancer Date: 2010-06-11 Impact factor: 27.401